However, the T-cell approach using check-point inhibitors, such as PD-1 or PD-L1, respond to only 18–28% of solid tumors (14, 29), and many studies have revealed that check-point inhibitors only have limitation to overcome immune escape at tumor microenvironments (30). The gene discussed is PDCD1; the disease is neoplasm.